0001209191-22-050954.txt : 20220921
0001209191-22-050954.hdr.sgml : 20220921
20220921195945
ACCESSION NUMBER: 0001209191-22-050954
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220919
FILED AS OF DATE: 20220921
DATE AS OF CHANGE: 20220921
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Soparkar Peter
CENTRAL INDEX KEY: 0001736315
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36579
FILM NUMBER: 221257657
MAIL ADDRESS:
STREET 1: C/O ADVERUM BIOTECHNOLOGIES, INC.
STREET 2: 100 CARDINAL WAY
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adverum Biotechnologies, Inc.
CENTRAL INDEX KEY: 0001501756
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 205258327
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CARDINAL WAY
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: (650) 649-1004
MAIL ADDRESS:
STREET 1: 100 CARDINAL WAY
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
FORMER COMPANY:
FORMER CONFORMED NAME: Avalanche Biotechnologies, Inc.
DATE OF NAME CHANGE: 20100921
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-09-19
0
0001501756
Adverum Biotechnologies, Inc.
ADVM
0001736315
Soparkar Peter
C/O ADVERUM BIOTECHNOLOGIES, INC.
100 CARDINAL WAY
REDWOOD CITY
CA
94063
0
1
0
0
See Remarks section
Common Stock
2022-09-19
4
S
0
13305
1.0697
D
273251
D
The sales reported on this Form 4 were effected to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain performance stock units.
Price reported is a weighted-average sale price. The shares were sold at prices ranging from $1.069589 to $1.0728. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Includes 6,000 shares purchased on May 20, 2022 pursuant to the Issuer's 2014 Employee Stock Purchase Plan, as amended and restated.
chief Operating Officer and Chief and Chief Legal Officer
Peter Soparkar, by /s/ Ron A. Metzger, Attorney-in-Fact
2022-09-21